Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2020

View Archived Issues

Immunocytokines jumpstart anti-glioblastoma immunity

Structural insights into small-molecule GLP-1 agonists

FDA clears IND for phase I/IIa study of AstroStem-V to treat COVID-19 patients with pneumonia

Enrollment begins in phase II ASUNCTIS study of asunercept in patients with COVID-19

NIH launches ACTIV-5/BET trial to identify new promising COVID-19 treatments

New osteoporosis treatment target, inhibitor identified

Universita degli Studi di Milano and collaborators describe inhibitors of miR-129

Cyclerion provides updates on their development of olinciguat and IW-6463

New MAP3K5 inhibitors identified at Enanta Pharmaceuticals

California Institute of Technology, 1200 Pharma and UC Oakland disclose PRMT5 inhibitors

Columbia University, Forkhead BioTherapeutics synthesize new FOXO1 inhibitors

New galectin-3 inhibitors discovered at Bristol Myers Squibb

Novan presents positive in vitro data for its NITRICIL platform technology against SARS-CoV-2

FDA grants approval for expanded use of Wakix for cataplexy in adult patients with narcolepsy

Sorrento cleared for phase II trial in Brazil of abivertinib for mild, moderate and severe COVID-19

Arvinas announces new preclinical programs

Janssen begins phase III evaluation of seltorexant as adjunctive therapy for MDD with insomnia

Astellas describes discovery of novel PET probe for fatty acid oxidation

First subject dosed in phase I study of AZP-3601

FDA clears IND for 177Lu-omburtamab-DTPA

KKC-080106 shows promising neuroprotective activity in preclinical models

Ankasa begins phase Ib/IIa evaluation of ART352-L in posterolateral spinal fusion

Roche begins phase III study of GDC-9545 with palbociclib in advanced breast cancer

FDA approves Inmazeb for Zaire ebolavirus

Vertex discontinues development of VX-814 for alpha-1 antitrypsin deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...